Abstract:Background: Positron emission tomography (PET) is an important tool for assessing coronary artery disease (CAD), but its widespread utilization is limited due to various factors, including limited local champion availability. This study aims to compare the frequency of PET procedures and their interpreters with other common CAD assessment modalities. Methods: Using Medicare data, we examined the number of cardiac PET procedures billed and compared them with single-photon emission computed tomography (SPECT), coronary computed tomography angiography (CCTA), stress magnetic resonance imaging (MRI), and stress echocardiography. Healthcare Common Procedure Coding System (HCPCS) codes were used to identify procedures. We calculated the total number of PET MPI procedures, the proportion of PET/CT and MBF assessments, and the median number of studies read per physician. We also analyzed the trends in the use of different CAD assessment modalities between 2018 and 2022. Descriptive statistics summarized the data. Results: In 2022, Medicare billed for 212,106 PET MPI scans. SPECT was six times more frequent (1,343,519), while stress echocardiography (201,676) and CCTA (118,734) had similar or lower use. Stress MRI (3,932) was least used. Of the PET MPI scans, 46% were PET/CT, and 39% included MBF measurements. Cardiologists interpreted 86% of PET scans, with a median of 58 studies per reader; 23% interpreted ≤25 studies annually. SPECT had a median of 63 studies per reader, and CCTA, stress MRI, and stress echocardiography had medians of 27, 20, and 24, respectively. PET, CT, and MRI use increased from 2018 to 2022, while SPECT and stress echocardiography declined. Conclusion: In the Medicare population, PET is the second most frequently used modality for CAD assessment. However, PET/CT and MBF are underutilized, limiting diagnostic and prognostic capabilities. Efforts to enhance education and awareness of PET's advantages and to address barriers to its wider adoption are essential to maximize its clinical benefits and improve patient outcomes.

Cardiac CT angiography: Financial implications of different practice types

Right-sizing cardiac CT reimbursement through local and national efforts: A call to action for the imaging community

Cardiac CT: why, when, and how : Update 2019

Cardiac CT in the context of value-based care

SCCT Health Policy and Advocacy Efforts

Cardiac Positron Emission Tomography and Other Modalities for CAD Assessment: A Snapshot from the Medicare Data

The clinical utility of new cardiac imaging modalities in Australasian clinical practice

Cardiovascular Computed Tomography in the Diagnosis of Cardiovascular Disease: Beyond Lumen Assessment

Innovations in cardiac computed tomography: Imaging in coronary artery disease

A new business paradigm to make coronary CT angiography (CCTA) accessible to all

Healthcare Policy Statement on the Utility of Coronary Computed Tomography for Evaluation of Cardiovascular Conditions and Preventive Healthcare: From the Health Policy Working Group of the Society of Cardiovascular Computed Tomography

Cardiovascular computed tomography in cardiovascular disease: An overview of its applications from diagnosis to prediction

Impact of coronary CT angiography on the hospital outcome among patients admitted with AMI undergoing revascularization procedures in theUS

Radiomics in Cardiac Computed Tomography

Clinical audit of the image quality and customised contrast volume using P3T contrast injection software versus standard injection protocol in CT coronary angiography

The Role of Noninvasive Imaging in Coronary Artery Disease Detection, Prognosis, and Clinical Decision Making

Future of cardiac computed tomography

Coronary computed tomography angiography for clinical practice

Non-Contrast and Contrast-Enhanced Cardiac Computed Tomography Imaging in the Diagnostic and Prognostic Evaluation of Coronary Artery Disease

Cardiac Computed Tomography of Native Cardiac Valves

Imaging biomarkers in cardiac CT: moving beyond simple coronary anatomical assessment